Back to Search
Start Over
Mnemo Therapeutics Announces Publication in Cancer Discovery on Ablation of SUV39H1 for Long-Term Protection Against Solid Tumors.
- Source :
- Immunotherapy Weekly; 12/5/2023, p523-523, 1p
- Publication Year :
- 2023
-
Abstract
- Mnemo Therapeutics, a biotechnology company, has published a preclinical study in Cancer Discovery that demonstrates the potential of inactivating the enzyme SUV39H1 to enhance the differentiation and persistence of CAR T cells. The study shows that genetic ablation of SUV39H1 reprograms T cells to express memory-associated genes and reduce exhaustion-associated genes, leading to improved efficacy and protection against tumor relapse in mouse models of lung cancer and other solid tumors. The findings suggest that inactivating SUV39H1 could be a promising approach to improving the long-term success of immunotherapy treatments for tumors. [Extracted from the article]
- Subjects :
- THERAPEUTICS
T cells
TUMOR treatment
BIOTECHNOLOGY industries
TUMORS
ATRIAL flutter
Subjects
Details
- Language :
- English
- ISSN :
- 10908625
- Database :
- Complementary Index
- Journal :
- Immunotherapy Weekly
- Publication Type :
- Periodical
- Accession number :
- 173930723